• Home
  • Search Results
  • Knock-in of human BACE1 cleaves murine APP and reiterates Alzheimer-like phenotypes.

Knock-in of human BACE1 cleaves murine APP and reiterates Alzheimer-like phenotypes.

The Journal of neuroscience : the official journal of the Society for Neuroscience (2014-08-08)
Kaja Plucińska, Barry Crouch, David Koss, Lianne Robinson, Michael Siebrecht, Gernot Riedel, Bettina Platt
ABSTRACT

Key neuropathological hallmarks of Alzheimer's disease (AD) are elevated levels of amyloid β-peptide (Aβ) species generated via amyloid precursor protein (APP) endoproteolysis and cleavage by the rate-limiting β-site enzyme 1 (BACE1). Because rodents do not develop amyloid pathologies, we here investigated whether AD-like endophenotypes can be created in mice by expression of human bace1. To avoid pitfalls of existing models, we introduced hbace1 via knock-in under the control of the CaMKII α promoter into the safe HPRT locus. We report amyloidogenic processing of murine APP in the hBACE1 mice (termed PLB4), resulting in the formation of toxic APP metabolites that accumulate intra- and extraneuronally in hippocampus and cortex. Pronounced accumulation of Aβ*56 and Aβ hexamers in the absence of plaque deposition was detected in brain tissue from symptomatic PLB4 mice. Heightened levels of inflammation (gliosis) also appeared in several AD-related brain regions (dentate gyrus, hippocampal area CA1, piriform and parietal cortices) at 6 and 12 months of age. Behaviorally, deficits in habituation to a novel environment and semantic-like memory (social transmission of food preference) were detected from 3 to 4 months of age. Impairments in spatial learning strategies in long-term reference (water maze) and working memory (Y-maze) tasks presented at 6 months, and were distinct from reductions in locomotor activity and anxiety. Overall, our data indicate for the first time that targeted, subtle forebrain-specific expression through single gene knock-in of hBACE1 is sufficient to generate AD-relevant cognitive impairments amid corresponding histopathologies, confirming human BACE as the key parameter in amyloid pathogenesis.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Sodium azide, ReagentPlus®, ≥99.5%
Sigma-Aldrich
1,1,1,3,3,3-Hexafluoro-2-propanol, ≥99%
Sigma-Aldrich
Sodium azide, BioXtra
Sigma-Aldrich
Sodium azide, BioUltra, ≥99.5% (T)
Sigma-Aldrich
Sodium azide, purum p.a., ≥99.0% (T)
Supelco
1,1,1,3,3,3-Hexafluoro-2-propanol, for GC derivatization, LiChropur, ≥99.8%
Sigma-Aldrich
Anti-APP antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
Anti-APP antibody produced in rabbit, ~1.0 mg/mL, affinity isolated antibody
Sigma-Aldrich
Anti-APP antibody produced in rabbit, 1 mg/mL, affinity isolated antibody
Sigma-Aldrich
Anti-APP antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-APP antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
Anti-APP (Ab-668) antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-APP (ab2) antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-APP (ab3) antibody produced in rabbit, IgG fraction of antiserum
Sigma-Aldrich
Monoclonal Anti-APP antibody produced in mouse, clone 2C12, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Anti-APP (N-terminal) antibody produced in goat, affinity isolated antibody, buffered aqueous solution